DXRX Stock Overview
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Diaceutics PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£1.04 |
52 Week High | UK£1.10 |
52 Week Low | UK£0.79 |
Beta | 0.42 |
1 Month Change | 7.22% |
3 Month Change | 19.54% |
1 Year Change | 0.48% |
3 Year Change | 0.97% |
5 Year Change | 4.52% |
Change since IPO | 8.90% |
Recent News & Updates
Recent updates
Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity
Jan 31Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts
Jan 28Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)
Jul 24Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?
Feb 04Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 31Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?
Nov 27Shareholder Returns
DXRX | GB Life Sciences | GB Market | |
---|---|---|---|
7D | 0% | -5.2% | 2.3% |
1Y | 0.5% | -25.8% | 2.7% |
Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned -25.8% over the past year.
Return vs Market: DXRX underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
DXRX volatility | |
---|---|
DXRX Average Weekly Movement | 4.8% |
Life Sciences Industry Average Movement | 8.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: DXRX has not had significant price volatility in the past 3 months.
Volatility Over Time: DXRX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 151 | Ryan Keeling | https://www.diaceutics.com |
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network.
Diaceutics PLC Fundamentals Summary
DXRX fundamental statistics | |
---|---|
Market cap | UK£90.36m |
Earnings (TTM) | UK£6.00k |
Revenue (TTM) | UK£21.90m |
Over9,999x
P/E Ratio4.0x
P/S RatioIs DXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DXRX income statement (TTM) | |
---|---|
Revenue | UK£21.90m |
Cost of Revenue | UK£2.77m |
Gross Profit | UK£19.13m |
Other Expenses | UK£19.13m |
Earnings | UK£6.00k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 21, 2024
Earnings per share (EPS) | 0.000071 |
Gross Margin | 87.37% |
Net Profit Margin | 0.027% |
Debt/Equity Ratio | 0% |
How did DXRX perform over the long term?
See historical performance and comparison